clinical trial · NCT06509958
Phase Ⅱ Study of Adductor Canal Block With HR18034 for Postsurgical Pain Management in TKA
Shanghai Hengrui Pharmaceutical Co., Ltd.·phase2·terminated·n = 15
Postoperative Pain Management in Total Knee ArthroplastyHR18034Ropivacaine Hydrochloride Injection
brief summary
Phase Ⅱ, randomized, double-blind, comparator-controlled study to evaluate the efficacy, safety and pharmacokinetics of single injection adductor canal block with HR18034 for postoperative pain management in total knee arthroplasty compared with ropivacaine.
started
Aug 20, 2024
primary completion
Oct 10, 2024
completion
Oct 10, 2024
last updated
Oct 30, 2024
official title
A Phase Ⅱ Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Single Injection Adductor Canal Block With HR18034 for Postoperative Pain Management in Total Knee Arthroplasty
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol